Addison's Disease, also known as primary adrenal insufficiency, is a rare endocrine disorder where the adrenal glands do not produce sufficient steroid hormones, specifically cortisol and aldosterone.
Ask a research question about Addison's Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Addison's Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-16T20:19:38Z'
description: Addison's Disease, also known as primary adrenal insufficiency, is a rare endocrine disorder where the adrenal glands do not produce sufficient steroid hormones, specifically cortisol and aldosterone.
category: Endocrine
parents:
- Adrenal Insufficiency
- Autoimmune Disorder
prevalence:
- population: Global
percentage: Rare
evidence:
- reference: PMID:27210825
reference_title: "Is Adrenal Insufficiency a Rare Disease?"
supports: PARTIAL
snippet: Diagnosis is often delayed, probably partly because diseases of the adrenal or pituitary region that cause primary AI (PAI) or central AI are relatively rare conditions.
explanation: The literature mentions that diseases causing primary or central adrenal insufficiency are relatively rare, but it does not provide a specific percentage or confirm the rarity of Addison's Disease globally.
- reference: PMID:12072049
reference_title: "High prevalence and increasing incidence of Addison's disease in western Norway."
supports: PARTIAL
snippet: We found a higher prevalence of Addison's disease in western Norway than has previously been reported anywhere.
explanation: The study indicates a higher prevalence in a specific region (western Norway) but does not provide a global perspective on the rarity of Addison's Disease.
- reference: PMID:38562931
reference_title: "Rare copy number variation in autoimmune Addison's disease."
supports: PARTIAL
snippet: Autoimmune Addison's disease (AAD) is a rare but life-threatening endocrine disorder caused by an autoimmune destruction of the adrenal cortex.
explanation: The literature confirms that autoimmune Addison's Disease is rare, but it does not specify the percentage or provide a comprehensive global view.
- reference: PMID:33143829
reference_title: "Spectrum of Addison's Disease in Children."
supports: PARTIAL
snippet: Typical and atypical presentations of Addison's disease in children of Pakistani population are defined in this study which may assist in better management of Addison's patients.
explanation: The study discusses the presentation of Addison's Disease in a specific population (Pakistani children) but does not address the global rarity of the disease.
progression:
- phase: Onset
age_range: 30-50
evidence:
- reference: PMID:12072049
reference_title: "High prevalence and increasing incidence of Addison's disease in western Norway."
supports: NO_EVIDENCE
snippet: 'OBJECTIVE: Estimates of the prevalence of Addison''s disease in Caucasians have varied from 39 to 117 per million. We have carried out an epidemiological study to obtain a confident point prevalence estimate in the Norwegian population for the end of 1999, and to find out whether the incidence is changing.'
explanation: The study provides prevalence and incidence data but does not specify the age range for the onset of Addison's disease.
- reference: PMID:33143829
reference_title: "Spectrum of Addison's Disease in Children."
supports: NO_EVIDENCE
snippet: 'OBJECTIVE: To determine the clinical presentation of Addison''s disease in order to increase the awareness of presentation in Pakistani children.'
explanation: The study focuses on the clinical presentation of Addison's disease in children, not in the age range of 30-50 years.
- reference: PMID:23322510
reference_title: "What affects the quality of life in autoimmune Addison's disease?"
supports: NO_EVIDENCE
snippet: 'INTRODUCTION: Several studies have shown a reduced quality of life in patients with Addison''s disease, but little is known about the potential influences.'
explanation: The study discusses quality of life in Addison's disease patients but does not provide information on the age range of onset.
- reference: PMID:20400889
reference_title: "Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients."
supports: NO_EVIDENCE
snippet: 'INTRODUCTION: Little information is available on patients with adrenal insufficiency (AI) in regard to complaints before diagnosis, time until correct diagnosis, false diagnosis, and professional changes due to the diagnosis.'
explanation: The study discusses the delay in diagnosis of adrenal insufficiency and related complaints but does not specify the age range for the onset of Addison's disease.
- reference: PMID:31791082
reference_title: "[The Schmidt's Syndrome]."
supports: NO_EVIDENCE
snippet: 'HISTORY AND CLINICAL FINDINGS: We report the case within a 22-year-old patient, initially seen because of fatigue, weight loss and discoloration of the skin.'
explanation: The study discusses a case of a 22-year-old patient with Addison's disease, which does not fall within the age range of 30-50 years.
pathophysiology:
- name: Autoimmune Adrenalitis
description: The immune system mistakenly attacks the adrenal cortex, leading to destruction of adrenal tissue and decreased hormone production. Lymphocytic infiltration of zona glomerulosa and zona fasciculata causes progressive loss of steroidogenic cells.
cell_types:
- preferred_term: CD8-positive, alpha-beta cytotoxic T cell
term:
id: CL:0000794
label: CD8-positive, alpha-beta cytotoxic T cell
- preferred_term: T-helper 1 cell
term:
id: CL:0000545
label: T-helper 1 cell
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: adaptive immune response
term:
id: GO:0002250
label: adaptive immune response
- preferred_term: T cell mediated cytotoxicity
term:
id: GO:0001913
label: T cell mediated cytotoxicity
- preferred_term: type 1 immune response
term:
id: GO:0042088
label: T-helper 1 type immune response
- preferred_term: antigen processing and presentation of peptide antigen via MHC class II
term:
id: GO:0002495
label: antigen processing and presentation of peptide antigen via MHC class II
locations:
- preferred_term: adrenal cortex
term:
id: UBERON:0001235
label: adrenal cortex
- preferred_term: zona glomerulosa of adrenal gland
term:
id: UBERON:0002053
label: zona glomerulosa of adrenal gland
- preferred_term: zona fasciculata of adrenal gland
term:
id: UBERON:0002054
label: zona fasciculata of adrenal gland
downstream:
- target: Reduced Cortisol Production
- target: Reduced Aldosterone Production
evidence:
- reference: PMID:29631795
reference_title: "Autoimmune Addison's disease - An update on pathogenesis."
supports: SUPPORT
snippet: Autoimmunity against the adrenal cortex is the leading cause of Addison's disease in industrialized countries... The immune-mediated attack on adrenocortical cells cripples their ability to synthesize vital steroid hormones.
explanation: The provided literature supports that the immune system mistakenly attacks the adrenal cortex, leading to reduced hormone production.
- reference: PMID:1946105
reference_title: "Tuberculous Addison's disease."
supports: SUPPORT
snippet: In most cases, autoimmune destruction of the adrenal cortex is the cause of Addison's disease.
explanation: This reference confirms that autoimmune destruction of the adrenal cortex leads to Addison's disease.
- reference: PMID:20357943
reference_title: "Canine hypoadrenocorticism: part I."
supports: SUPPORT
snippet: Hypoadrenocorticism typically results from immune-mediated destruction of all adrenocortical layers, resulting in deficiencies of min-eralocorticoids (aldosterone) and glucocorticoids (cortisol).
explanation: The literature supports the statement that the immune system attacks the adrenal cortex, leading to reduced cortisol and aldosterone production.
- reference: PMID:34996091
reference_title: "Mistaken Identity: The Role of Autoantibodies in Endocrine Disease."
supports: SUPPORT
snippet: The immune system mistakenly attacks one's own cells, as if they were foreign, which typically results in endocrine gland hypofunction and inadequate hormone production... conditions such as Addison disease are encountered less frequently.
explanation: This reference supports the idea that autoimmune processes lead to endocrine gland hypofunction, including Addison's disease.
- name: Reduced Cortisol Production
description: Lack of cortisol impacts the body's ability to respond to stress and maintain various metabolic functions. Impaired gluconeogenesis, decreased vascular tone, and altered immune responses result from cortisol deficiency.
biological_processes:
- preferred_term: glucocorticoid biosynthetic process
term:
id: GO:0006704
label: glucocorticoid biosynthetic process
modifier: DECREASED
- preferred_term: gluconeogenesis
term:
id: GO:0006094
label: gluconeogenesis
modifier: DECREASED
- preferred_term: response to stress
term:
id: GO:0006950
label: response to stress
modifier: ABNORMAL
downstream:
- target: Hypoglycemia
- target: Weight Loss
evidence:
- reference: PMID:16828409
reference_title: "Addison's disease."
supports: SUPPORT
snippet: Addison's disease, or primary adrenal insufficiency, results in glucocorticoid and mineralocorticoid deficiency... chronic primary adrenal insufficiency presents with a more insidious history of malaise, anorexia, diarrhea, weight loss... hypoglycemia characterize acute adrenal crisis.
explanation: The literature describes Addison's disease as resulting in glucocorticoid (cortisol) deficiency, which leads to symptoms such as hypoglycemia and weight loss.
- reference: PMID:30120786
reference_title: "Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy."
supports: SUPPORT
snippet: Adrenal insufficiency (AI) is a rare, life-threatening disorder characterized by insufficient production of corticosteroid hormones... Conventional treatment of both primary and secondary adrenal insufficiencies involves lifelong glucocorticoid replacement therapy.
explanation: The literature confirms that adrenal insufficiency, which includes Addison's disease, is characterized by insufficient cortisol production and requires glucocorticoid replacement therapy.
- name: Reduced Aldosterone Production
description: Insufficient aldosterone affects the balance of sodium and potassium in the body, leading to dehydration and low blood pressure. Impaired sodium retention and potassium excretion in renal tubules cause electrolyte disturbances.
biological_processes:
- preferred_term: mineralocorticoid biosynthetic process
term:
id: GO:0006705
label: mineralocorticoid biosynthetic process
modifier: DECREASED
- preferred_term: sodium ion transport
term:
id: GO:0006814
label: sodium ion transport
modifier: ABNORMAL
- preferred_term: potassium ion transport
term:
id: GO:0006813
label: potassium ion transport
modifier: ABNORMAL
locations:
- preferred_term: zona glomerulosa of adrenal gland
term:
id: UBERON:0002053
label: zona glomerulosa of adrenal gland
downstream:
- target: Hyponatremia
- target: Hyperkalemia
evidence:
- reference: PMID:6091953
reference_title: "Disorders of the adrenal cortex: their effects on electrolyte metabolism."
supports: SUPPORT
snippet: On the other hand, impaired secretion, as in Addison's disease or in congenital deficiencies of other steroid-synthesizing enzymes, leads to hypotension, sodium loss with hypovolaemia, and hyperkalaemia.
explanation: The excerpt clearly supports the statement by mentioning the effects of impaired aldosterone secretion in Addison's disease, which includes sodium loss (hyponatremia), hypovolemia (dehydration), and hyperkalemia.
- reference: PMID:28132947
reference_title: "An Addison disease revealed with a serious hyponatremia."
supports: SUPPORT
snippet: Addison's disease is characterized by the destruction of the adrenal cortex. Autoimmune adrenalitis is the main cause of adrenal insufficiency. Treatment involves normalisation of sodium concentration and corticosteroids replacement.
explanation: The literature states that Addison's disease involves the destruction of the adrenal cortex, leading to issues with sodium concentration, supporting the statement about insufficient aldosterone affecting sodium and potassium balance.
- reference: PMID:13851580
reference_title: "Addison's disease."
supports: NO_EVIDENCE
snippet: Addison's disease.
explanation: The reference title directly mentions Addison's disease, supporting the context of the statement.
- name: Polygenic Susceptibility
description: Multiple genetic risk loci contribute to autoimmune Addison's disease susceptibility, including HLA class II haplotypes and immune regulatory genes. HLA-DR3-DQ2 and HLA-DR4-DQ8 alter antigen presentation, while non-HLA genes affect T-cell regulation, checkpoint signaling, and inflammatory responses.
genes:
- preferred_term: HLA-DRB1
- preferred_term: HLA-DQA1
- preferred_term: HLA-DQB1
- preferred_term: CTLA4
term:
id: hgnc:2505
label: CTLA4
- preferred_term: PTPN22
term:
id: hgnc:9652
label: PTPN22
- preferred_term: BACH2
term:
id: hgnc:14078
label: BACH2
- preferred_term: CLEC16A
term:
id: hgnc:29013
label: CLEC16A
- preferred_term: NLRP1
term:
id: hgnc:14374
label: NLRP1
- preferred_term: CIITA
term:
id: hgnc:7067
label: CIITA
- preferred_term: STAT4
term:
id: hgnc:11365
label: STAT4
biological_processes:
- preferred_term: negative regulation of T cell receptor signaling pathway
term:
id: GO:0050860
label: negative regulation of T cell receptor signaling pathway
modifier: ABNORMAL
- preferred_term: antigen processing and presentation
term:
id: GO:0019882
label: antigen processing and presentation
modifier: ABNORMAL
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
modifier: INCREASED
downstream:
- target: Autoimmune Adrenalitis
notes: GWAS identified HLA and non-HLA loci explaining approximately 35-41% of heritability
phenotypes:
- category: Endocrine
name: Fatigue
frequency: VERY_FREQUENT
evidence:
- reference: PMID:8325289
reference_title: "Acute adrenal insufficiency."
supports: SUPPORT
snippet: A constellation of nonspecific symptoms including weakness, easy fatigue, nausea, anorexia, and weight loss are typical features of adrenal insufficiency.
explanation: The literature indicates that fatigue is a typical feature of adrenal insufficiency, which includes Addison's Disease.
- reference: PMID:21365946
reference_title: "[Addison's disease imitating fibromyalgia]."
supports: SUPPORT
snippet: We present the case of a 33-year-old female with generalized pain in the musculoskeletal system, fatigue, and many other symptoms.
explanation: The literature supports that fatigue is a symptom of Addison's Disease.
- reference: PMID:31791082
reference_title: "[The Schmidt's Syndrome]."
supports: SUPPORT
snippet: We report the case within a 22-year-old patient, initially seen because of fatigue, weight loss and discoloration of the skin.
explanation: The literature supports that fatigue is a symptom of Addison's Disease.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Gastrointestinal
name: Abdominal Pain
frequency: FREQUENT
evidence:
- reference: PMID:2801683
reference_title: "Gastrointestinal manifestations of Addison's disease."
supports: SUPPORT
snippet: Eight had severe or unusual gastrointestinal symptoms at presentation. One, already known to have Addison's disease, required several admissions to the hospital because of unexplained abdominal pain and vomiting before inadequate glucocorticoid replacement was diagnosed.
explanation: The reference clearly indicates that patients with Addison's disease frequently present with severe gastrointestinal symptoms, including abdominal pain.
- reference: PMID:3044463
reference_title: "Abdominal pain, indigestion, anorexia, nausea and vomiting."
supports: NO_EVIDENCE
snippet: Non-specific abdominal complaints are a very frequent cause of discomfort. Even if only comparatively few are brought to the attention of the physician, they account for a considerable portion of the reasons for seeking medical care, both in acute and chronic conditions.
explanation: The reference discusses the frequency of non-specific abdominal complaints, which are common in various conditions, including Addison's disease.
- reference: PMID:21365946
reference_title: "[Addison's disease imitating fibromyalgia]."
supports: NO_EVIDENCE
snippet: She was initially diagnosed with fibromyalgia but other tests finally confirmed Addison's disease. Supplementation with adrenal hormones resulted in total remission of pain and of other symptoms.
explanation: The reference indicates that generalized pain, including abdominal pain, was a symptom in a patient with Addison's disease.
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
- category: Endocrine
name: Hyperpigmentation
frequency: VERY_FREQUENT
diagnostic: true
notes: Especially noticeable in areas exposed to friction, such as knuckles, elbows, and knees.
evidence:
- reference: PMID:33951364
reference_title: "Hyperpigmentation from Addison's Disease."
supports: SUPPORT
snippet: Hyperpigmentation from Addison's Disease.
explanation: The title directly indicates that hyperpigmentation is associated with Addison's Disease.
- reference: PMID:21219212
reference_title: "Misdiagnosis of Addison's disease in a patient with end-stage renal disease."
supports: SUPPORT
snippet: The physical examination was completely normal except for muscle weakness, hyperpigmentation on labial mucosa and skin in a patient.
explanation: The abstract mentions hyperpigmentation as a clinical finding in a patient with Addison's disease.
- reference: PMID:33143829
reference_title: "Spectrum of Addison's Disease in Children."
supports: SUPPORT
snippet: Increased skin pigmentation was observed in 45 children with other identifiable features including weight loss, lethargy, and poor response in activities.
explanation: The study found increased skin pigmentation in a significant number of children with Addison's disease.
- reference: PMID:28717080
reference_title: "Addison's Disease Caused by Tuberculosis with Atypical Hyperpigmentation and Active Pulmonary Tuberculosis."
supports: SUPPORT
snippet: Addison's disease caused by tuberculosis characterized by atypical hyperpigmentation, noted as exacerbation of the pigmentation of freckles and the occurrence of new freckles.
explanation: The case report highlights hyperpigmentation as a symptom of Addison's disease caused by tuberculosis.
- reference: PMID:34932395
reference_title: "Not the final diagnosis: from Addison's disease to POEMS syndrome: a case report and literature review."
supports: SUPPORT
snippet: We report the case of a 47-year-old male patient with pigmentation of the head, face and hands, who was initially diagnosed as having primary adrenal insufficiency (Addison's disease).
explanation: The abstract mentions hyperpigmentation in a patient initially diagnosed with Addison's disease.
phenotype_term:
preferred_term: Hyperpigmentation
term:
id: HP:0000953
label: Hyperpigmentation of the skin
- category: Musculoskeletal
name: Muscle Weakness
frequency: FREQUENT
evidence:
- reference: PMID:36210660
reference_title: "Broad Complex Tachycardia, Addison's disease, and Ascending Flacid Paralysis: An Interesting Case on Cardiology Floor."
supports: SUPPORT
snippet: His clinical presentation was due to hyperkalemia and weakness due to Addison's disease.
explanation: This case report describes muscle weakness as a clinical presentation of Addison's disease.
- reference: PMID:23897142
reference_title: "[Acute muscle weakness: differential diagnoses]."
supports: NO_EVIDENCE
snippet: Acute muscle weakness, a common disorder in pediatrics, can occur from impairment of any part of the motor unit, including the upper motor neuron, lower motor neuron, peripheral nerve, neuromuscular junction or muscle.
explanation: This reference discusses acute muscle weakness as a common disorder, implying that muscle weakness can be a frequent symptom in various conditions, including Addison's disease.
- reference: PMID:21365946
reference_title: "[Addison's disease imitating fibromyalgia]."
supports: PARTIAL
snippet: Supplementation with adrenal hormones resulted in total remission of pain and of other symptoms.
explanation: This case report mentions muscle pain and weakness that were misdiagnosed as fibromyalgia but were actually due to Addison's disease, which resolved with appropriate treatment.
phenotype_term:
preferred_term: Muscle weakness
term:
id: HP:0001324
label: Muscle weakness
- category: Systemic
name: Weight Loss
frequency: FREQUENT
evidence:
- reference: PMID:13280719
reference_title: "Addison's disease presenting as loss of weight without pigmentation."
supports: SUPPORT
snippet: Addison's disease presenting as loss of weight without pigmentation.
explanation: The reference clearly states that weight loss is a presenting symptom of Addison's disease.
- reference: PMID:23893277
reference_title: "Addison's disease and its associations."
supports: SUPPORT
snippet: Addison's disease is a relatively rare endocrine condition resulting from adrenal insufficiency due to various causes. Weight loss is a common feature.
explanation: The literature identifies weight loss as a common feature of Addison's disease.
- reference: PMID:31791082
reference_title: "[The Schmidt's Syndrome]."
supports: SUPPORT
snippet: We report the case within a 22-year-old patient, initially seen because of fatigue, weight loss and discoloration of the skin.
explanation: The reference describes weight loss as one of the presenting symptoms in a patient with Addison's disease.
- reference: PMID:23308244
reference_title: "Addison's disease symptoms--a cross sectional study in urban South Africa."
supports: SUPPORT
snippet: Hyperpigmentation was observed in 76%, nausea and vomiting occurred in more than 40%, and weight loss was noted in 25%.
explanation: The study reports weight loss in 25% of Addison's disease patients, supporting the statement that it is a frequent symptom.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Cardiovascular
name: Hypotension
frequency: FREQUENT
evidence:
- reference: PMID:22975403
reference_title: "[Hypotension from endocrine origin]."
supports: SUPPORT
snippet: Hypotension is defined by a low blood pressure either permanently or only in upright posture (orthostatic hypotension). ... Chronic hypotension from endocrine origin may be linked to adrenal failure from adrenal or central origin
explanation: The reference clearly states that chronic hypotension can be linked to adrenal failure, which is a characteristic of Addison's disease.
- reference: PMID:27992012
reference_title: "Conduct protocol in emergency: Acute adrenal insufficiency."
supports: SUPPORT
snippet: Addisonian crisis is a difficult diagnosis due to the unspecificity of its signs and symptoms. Nevertheless, it can be suspected in patients who enter the emergency room with complaints of abdominal pain, hypotension unresponsive to volume or vasopressor agents...
explanation: The reference indicates that hypotension is a symptom of Addisonian crisis, which is part of Addison's disease.
- reference: PMID:36709280
reference_title: "Coronary artery disease in a patient with Addison's disease: a case report and literature review."
supports: SUPPORT
snippet: We reported a 51-year-old male patient with unstable angina pectoris and hypotension. Changes on coronary angiography within 2 years suggested rapid progression of coronary artery disease in a patient with low cardiovascular risk. An additional clue of skin hyperpigmentation, fatigue and further examination confirmed the diagnosis of Addison's disease...
explanation: The reference mentions hypotension in a patient diagnosed with Addison's disease, supporting the statement.
phenotype_term:
preferred_term: Hypotension
term:
id: HP:0002615
label: Hypotension
- category: Endocrine
name: Salt Craving
frequency: OCCASIONAL
evidence:
- reference: PMID:20964584
reference_title: "Endocrine disorders: causes of hyponatremia not to neglect."
supports: SUPPORT
snippet: Primary adrenal insufficiency (i.e. Addison's disease) may well be recognized by clear hall-marks of the disease, such as pigmentation, salt craving, hypotension, and concomitant hyperkalemia.
explanation: The literature explicitly mentions salt craving as a hallmark of Addison's disease, confirming the statement.
phenotype_term:
preferred_term: Salt Craving
term:
id: HP:0030083
label: Salt craving
- category: Metabolic
name: Hypoglycemia
frequency: FREQUENT
notes: Due to decreased cortisol impairing gluconeogenesis
phenotype_term:
preferred_term: Hypoglycemia
term:
id: HP:0001943
label: Hypoglycemia
- category: Metabolic
name: Hyponatremia
frequency: FREQUENT
notes: Low sodium due to aldosterone deficiency and impaired sodium retention
phenotype_term:
preferred_term: Hyponatremia
term:
id: HP:0002902
label: Hyponatremia
- category: Metabolic
name: Hyperkalemia
frequency: FREQUENT
notes: Elevated potassium due to aldosterone deficiency and impaired potassium excretion
phenotype_term:
preferred_term: Hyperkalemia
term:
id: HP:0002153
label: Hyperkalemia
- category: Systemic
name: Adrenal Crisis
frequency: OCCASIONAL
diagnostic: true
notes: Acute life-threatening decompensation with severe hypotension and shock, often precipitated by stress, infection, or trauma. Also known as Addisonian crisis.
- category: Endocrine
name: Nausea and Vomiting
frequency: FREQUENT
notes: Common gastrointestinal manifestations of glucocorticoid deficiency
phenotype_term:
preferred_term: Nausea and vomiting
term:
id: HP:0002017
label: Nausea and vomiting
biochemical:
- name: Cortisol
presence: Decreased
context: Diagnostic indicator, measured in blood or saliva
evidence:
- reference: PMID:18954859
reference_title: "[News for adrenal insufficiency]."
supports: SUPPORT
snippet: Diagnosis of AI often requires serum cortisol measurement during dynamic tests. Salivary cortisol measurement was reported to have an equivalent diagnostic performance to serum cortisol and that is even better when CBG levels are altered.
explanation: This reference supports the statement as it indicates that cortisol levels, whether measured in blood or saliva, are used for diagnosing adrenal insufficiency, which includes Addison's Disease.
- reference: PMID:31791082
reference_title: "[The Schmidt's Syndrome]."
supports: SUPPORT
snippet: Addison's disease was diagnosed by management of cortisol, ACTH and adrenal antibodies.
explanation: This reference supports the statement by indicating that cortisol levels are used as a diagnostic indicator for Addison's Disease.
- reference: PMID:25647239
reference_title: "Measurement of salivary cortisol level for the diagnosis of critical illness-related corticosteroid insufficiency in children."
supports: SUPPORT
snippet: Salivary cortisol can be used as a surrogate for serum free cortisol in critically ill pediatric patients. Salivary cortisol is a cost-effective and less invasive measure of bioavailable cortisol and offers an alternate and accurate method for assessing critical illness-related corticosteroid insufficiency in children.
explanation: This reference supports the statement by indicating that salivary cortisol is an accurate method for assessing cortisol levels, which are relevant for diagnosing conditions like Addison's Disease.
- reference: PMID:19414006
reference_title: "Cortisol assays and diagnostic laboratory procedures in human biological fluids."
supports: SUPPORT
snippet: The overview of cortisol physiology, action and pathology is achieved in relation to the hypothalamic-pituitary-adrenal axis alteration by laboratory investigation. The measurements of cortisol and related compound levels in blood, urine and saliva used to study the physiological and pathological cortisol involvement, are critically reviewed.
explanation: This reference supports the statement by discussing the measurement of cortisol levels in various biological fluids, including blood and saliva, for diagnosing conditions related to cortisol imbalance such as Addison's Disease.
- name: ACTH (Adrenocorticotropic Hormone)
presence: Increased
context: Elevated due to lack of feedback inhibition by cortisol
evidence:
- reference: PMID:28132947
reference_title: "An Addison disease revealed with a serious hyponatremia."
supports: SUPPORT
snippet: The serum concentration of ACTH and 21-hydroxylase antibodies were increased and lead to the diagnosis.
explanation: The elevated ACTH levels are indicative of Addison's disease due to lack of feedback inhibition by cortisol.
- reference: PMID:19500760
reference_title: "The genetics of familial glucocorticoid deficiency."
supports: SUPPORT
snippet: Patients present in early life with low or undetectable cortisol and--because of the failure of the negative feedback loop to the pituitary and hypothalamus--grossly elevated ACTH levels.
explanation: The elevated ACTH levels in Addison's disease are due to the failure of cortisol to provide negative feedback.
- reference: PMID:22066755
reference_title: "Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies."
supports: SUPPORT
snippet: Compared with nonprogressors, in the time period 2 months-2 years prior to the onset of AD, progressors were significantly more likely to have elevated ACTH.
explanation: This study shows that elevated ACTH levels can precede the onset of Addison's disease due to impaired feedback inhibition by cortisol.
- name: Aldosterone
presence: Decreased
evidence:
- reference: PMID:24428320
reference_title: "Evaluation of aldosterone concentrations in dogs with hypoadrenocorticism."
supports: SUPPORT
snippet: Baseline and ACTH-stimulated aldosterone was significantly lower in dogs with HA than in the other groups. Aldosterone was low or undetectable in 67/70 dogs with HA independently of sodium and potassium levels.
explanation: The study shows that aldosterone levels are significantly lower in dogs with hypoadrenocorticism (HA), which is analogous to Addison's disease in humans.
- reference: PMID:32101828
reference_title: "A 29-year-old patient with adrenoleukodystrophy presenting with Addison's disease."
supports: SUPPORT
snippet: Endocrinological examination showed low serum cortisol (1.2 mug/dL) with high plasma ACTH (4,750 pg/mL), and abdominal computed tomography showed normal adrenal glands.
explanation: This case study of a patient with Addison's disease form of adrenoleukodystrophy indicates primary adrenal insufficiency, which typically involves decreased aldosterone levels.
- reference: PMID:28132947
reference_title: "An Addison disease revealed with a serious hyponatremia."
supports: SUPPORT
snippet: Addison's disease is characterized by the destruction of the adrenal cortex. Autoimmune adrenalitis is the main cause of adrenal insufficiency.
explanation: The destruction of the adrenal cortex in Addison's disease leads to decreased production of adrenal hormones, including aldosterone.
- reference: PMID:25138826
reference_title: "Management of hypertension and heart failure in patients with Addison's disease."
supports: SUPPORT
snippet: Addison's disease may be complicated by hypertension and less commonly by heart failure. We review the pathophysiology of the renin-angiotensin-aldosterone axis in Addison's disease and how this is altered in the setting of hypertension and heart failure.
explanation: The article discusses the altered renin-angiotensin-aldosterone axis in Addison's disease, indicating decreased aldosterone production.
- reference: PMID:5797781
reference_title: "Thyroid function in Addison's disease."
supports: NO_EVIDENCE
snippet: Clinical evidence of a thyroid disorder was present in 10 out of 40 patients with Addison's disease.
explanation: The study indirectly supports the statement by discussing adrenal insufficiency in Addison's disease, which typically includes decreased aldosterone levels.
diagnosis:
- name: ACTH Stimulation Test
notes: Evaluates adrenal gland function by measuring cortisol response to synthetic ACTH
evidence:
- reference: PMID:30855285
reference_title: "Pitfalls in the interpretation of the cosyntropin stimulation test for the diagnosis of adrenal insufficiency."
supports: SUPPORT
snippet: The ACTH stimulation test is commonly performed in patients suspected of having adrenal insufficiency when the basal serum cortisol levels are inconclusive.
explanation: This reference discusses the use of the ACTH stimulation test to evaluate adrenal gland function by measuring cortisol response.
- reference: PMID:2008821
reference_title: "Addison's disease."
supports: SUPPORT
snippet: The rapid adrenocorticotropic hormone (ACTH) stimulation test is useful for identifying adrenal insufficiency.
explanation: This reference confirms the use of the ACTH stimulation test for evaluating adrenal function.
- reference: PMID:29572711
reference_title: "Low-dose Synachten test with measurement of salivary cortisol in adult patients with β-thalassemia major."
supports: SUPPORT
snippet: Patients were tested with 1 µg ACTH for serum and salivary cortisol.
explanation: This reference supports the use of the ACTH stimulation test to measure cortisol response, which is relevant to evaluating adrenal gland function.
- reference: PMID:24170102
reference_title: "Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment."
supports: SUPPORT
snippet: We aimed to determine whether tetracosactide (synthetic ACTH1-24) could revive adrenal steroidogenic function in autoimmune Addison's disease.
explanation: This reference discusses the use of synthetic ACTH to stimulate adrenal function, supporting the statement.
- name: Serum Electrolyte Panel
notes: May show hyponatremia and hyperkalemia
evidence:
- reference: PMID:20964584
reference_title: "Endocrine disorders: causes of hyponatremia not to neglect."
supports: SUPPORT
snippet: Primary adrenal insufficiency (i.e. Addison's disease) may well be recognized by clear hall-marks of the disease, such as pigmentation, salt craving, hypotension, and concomitant hyperkalemia.
explanation: The literature indicates that hyperkalemia is a hallmark of Addison's disease.
- reference: PMID:32086340
reference_title: "Problem solving in clinical practice: the sick infant with low sodium and high potassium."
supports: PARTIAL
snippet: Many paediatricians will be faced with a sick infant who on investigation is found to have hyponatraemia and hyperkalaemia at some time in their career.
explanation: The literature describes cases where patients with Addison's disease present with hyponatremia and hyperkalemia.
- reference: PMID:14433865
reference_title: "Hyperkalemic neuromyopathy in Addison's disease."
supports: SUPPORT
snippet: Hyperkalemic neuromyopathy in Addison's disease.
explanation: The title itself indicates that hyperkalemia is associated with Addison's disease.
- reference: PMID:8680923
reference_title: "Atypical Addison's disease in the dog: a retrospective survey of 14 cases."
supports: PARTIAL
snippet: Ninety-three percent of the cases had either hyponatremia without hyperkalemia or normal serum electrolyte concentrations.
explanation: The literature shows that while hyponatremia is common, hyperkalemia is not always present in dogs with Addison's disease.
- reference: PMID:34932395
reference_title: "Not the final diagnosis: from Addison's disease to POEMS syndrome: a case report and literature review."
supports: NO_EVIDENCE
snippet: We report the case of a 47-year-old male patient with pigmentation of the head, face and hands, who was initially diagnosed as having primary adrenal insufficiency (Addison's disease).
explanation: The case report suggests that Addison's disease may be associated with electrolyte imbalances including hyponatremia and hyperkalemia.
genetic:
- name: CYP21A2 (21-hydroxylase)
association: Major adrenal autoantigen; autoantibodies target this enzyme
notes: Target of autoantibodies and autoreactive T cells in autoimmune Addison's disease
evidence:
- reference: PMID:34665570
reference_title: "The natural history of 21-hydroxylase autoantibodies in autoimmune Addison's disease."
supports: SUPPORT
snippet: The most common cause of primary adrenal failure (Addison's disease) in the Western world is autoimmunity characterized by autoantibodies against the steroidogenic enzyme 21-hydroxylase (CYP21A2, 21OH)
explanation: This study demonstrates that 21-hydroxylase is the major autoantigen in autoimmune Addison's disease.
- name: AIRE
association: Autoimmune Polyendocrine Syndrome Type 1 (APS-1) is a known genetic cause
notes: Biallelic loss-of-function mutations cause breakdown of central tolerance in thymus
evidence:
- reference: PMID:33717087
reference_title: "Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence."
supports: SUPPORT
snippet: The autoimmune polyglandular syndrome type 1 (APS1) is caused by pathogenic variants of the autoimmune regulator (AIRE) gene.
explanation: The literature clearly states that APS1, which includes Addison's disease, is caused by mutations in the AIRE gene.
- reference: PMID:25667374
reference_title: "Genetic forms of adrenal insufficiency."
supports: SUPPORT
snippet: The genetic mutations associated with several familial causes of adrenal insufficiency have now been identified... autoimmune polyglandular syndrome type 1.
explanation: APS1 is listed among the genetic causes of adrenal insufficiency, which is directly related to Addison's disease.
- reference: PMID:24988226
reference_title: "New splice site acceptor mutation in AIRE gene in autoimmune polyendocrine syndrome type 1."
supports: SUPPORT
snippet: Autoimmune polyglandular syndrome type 1 (APS-1, OMIM 240300) is a rare autosomal recessive disorder... We identified a novel homozygous mutation in the splice site acceptor (SSA) of intron 5 (c.653-1G>A) in two siblings with different clinical outcomes of APS-1.
explanation: This study identifies specific mutations in the AIRE gene associated with APS1, which includes Addison's disease.
- reference: PMID:22344197
reference_title: "Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients."
supports: SUPPORT
snippet: Autoimmune polyendocrine syndrome type 1 (APS1) is a childhood-onset monogenic disorder caused by mutations in the autoimmune regulator (AIRE) gene.
explanation: The literature confirms that APS1 is caused by mutations in the AIRE gene, supporting the association with Addison's disease.
- reference: PMID:24014553
reference_title: "Addison's disease: a survey on 633 patients in Padova."
supports: SUPPORT
snippet: Of the patients with APS1, 96% were revealed to have AIRE gene mutations.
explanation: The high prevalence of AIRE gene mutations in APS1 patients supports the genetic link to Addison's disease.
- name: HLA-DR3-DQ2 and HLA-DR4-DQ8
association: HLA class II haplotypes strongly increase risk
notes: Polygenic susceptibility; altered peptide presentation to CD4+ T cells (HLA-DRB1, HLA-DQA1, HLA-DQB1)
evidence:
- reference: PMID:12392510
reference_title: "Additional association of intra-MHC genes, MICA and D6S273, with Addison's disease."
supports: SUPPORT
snippet: Susceptibility to Addison's disease is influenced by the genes around MICA and D6S273 for both the HLA DR3-DQ2 and DR4-DQ8 haplotypes
explanation: This study demonstrates that HLA-DR3-DQ2 and DR4-DQ8 haplotypes are major susceptibility markers for Addison's disease.
- name: CTLA4
association: Immune checkpoint regulator; risk variants reduce T-cell inhibition
notes: Target of immune checkpoint inhibitor drugs that can precipitate autoimmune adrenalitis
evidence:
- reference: PMID:26204230
reference_title: "CTLA-4 as a genetic determinant in autoimmune Addison's disease."
supports: SUPPORT
snippet: The G-allele of SNP rs231775 in CTLA-4 is associated with AAD in Norwegian patients (odds ratio (OR)=1.35 (confidence interval (CI) 1.10-1.66), P=0.004)
explanation: This study demonstrates that CTLA4 variants are a genetic susceptibility locus for autoimmune Addison's disease.
- name: PTPN22
association: Tyrosine phosphatase modulating T-cell receptor signaling
notes: Risk alleles perturb T-cell selection and activation
evidence:
- reference: PMID:18301444
reference_title: "Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease."
supports: SUPPORT
snippet: the 1858T-allele is a PTPN22 genetic susceptibility factor for autoimmune AD
explanation: This study demonstrates that PTPN22 1858T-allele is associated with autoimmune Addison's disease susceptibility.
- name: BACH2
association: Transcription factor controlling B- and T-cell differentiation
notes: Variants associated with autoimmunity and Addison's disease susceptibility
- name: CLEC16A
association: GWAS-implicated locus linked to antigen presentation and autophagy
notes: Contributes to polygenic autoimmune susceptibility
- name: NLRP1
association: Inflammasome component; variants implicate inflammatory pathways
notes: May modulate adrenal inflammation in autoimmune context
- name: CIITA
association: Master regulator of MHC class II expression
notes: Variation can alter antigen presentation and autoimmunity risk
- name: STAT4
association: Transcription factor promoting Th1 differentiation
notes: Implicated in directing Th1-biased responses in autoimmune Addison's disease
environmental:
- name: Infections
notes: Tuberculosis and other infections can cause adrenal damage leading to Addison’s disease
evidence:
- reference: PMID:1946105
reference_title: "Tuberculous Addison's disease."
supports: SUPPORT
snippet: In most cases, autoimmune destruction of the adrenal cortex is the cause of Addison's disease; however, as in the patient described here, tuberculosis is a possible cause.
explanation: The reference mentions tuberculosis as a possible cause of Addison's disease, supporting the statement that infections can lead to this condition.
- reference: PMID:30144040
reference_title: "The potential role for infections in the pathogenesis of autoimmune Addison's disease."
supports: PARTIAL
snippet: AAD is thought to be caused by an unfortunate combination of genetic and environmental factors. ... A major environmental factor commonly proposed for autoimmune diseases ... is viral infections.
explanation: While this reference discusses viral infections as a potential environmental factor for autoimmune Addison's disease, it does not confirm the role of infections in general.
- reference: PMID:35345086
reference_title: "Addison's disease due to histoplasmosis of bilateral adrenal glands in a previously treated extrapulmonary tuberculosis case."
supports: SUPPORT
snippet: Addison's disease due to histoplasmosis of bilateral adrenal glands in a previously treated extrapulmonary tuberculosis case.
explanation: This reference supports the statement by showing that histoplasmosis, an infection, caused Addison's disease in a patient with a history of tuberculosis.
- reference: PMID:36274124
reference_title: "Addison's disease triggered by infection with mycobacterium abscessus, but not by adrenal tuberculosis or MAC pulmonary disease, in a subject with type 2 diabetes mellitus: case report."
supports: SUPPORT
snippet: It is known that infection is one of main causes of Addison's disease. Among various infections, tuberculous infection accounts for the majority of them.
explanation: The reference clearly states that infections, including tuberculosis, are major causes of Addison's disease, supporting the statement.
- reference: PMID:15251839
reference_title: "Addisonian crisis and tuberculous epididymo-orchitis."
supports: SUPPORT
snippet: In a patient from a country where tuberculosis is endemic, tuberculosis should be considered in the differential diagnosis when primary adrenal insufficiency is detected, especially in association with enlarged or calcified adrenal glands.
explanation: This reference supports the statement by indicating that tuberculosis should be considered a potential cause of primary adrenal insufficiency, which is synonymous with Addison's disease.
exposure_term:
preferred_term: Infectious agent exposure
term:
id: ECTO:3000000
label: exposure to organism
treatments:
- name: Glucocorticoid Replacement
description: Hydrocortisone or prednisone to replace cortisol.
evidence:
- reference: PMID:18363515
reference_title: "Replacement therapy for Addison's disease: recent developments."
supports: PARTIAL
snippet: Starting doses of glucocorticoids should be 15 - 20 mg for hydrocortisone or 20 - 30 mg for cortisone acetate, divided into two or three doses, and preferentially weight-adjusted. There are indications that the synthetic glucocorticoids have undesirable metabolic long-term effects, which make them less suitable as first-line treatment.
explanation: The statement mentions prednisone, but the reference specifically discusses hydrocortisone and cortisone acetate, not prednisone.
- reference: PMID:22695777
reference_title: "[Perioperative Addisonian crisis]."
supports: PARTIAL
snippet: This necessitated an aggressive volume therapy in addition to an initial therapy with 100 mg hydrocortisone, 8 g glucose and a continuous administration of catecholamines.
explanation: The reference supports the use of hydrocortisone but does not mention prednisone.
- reference: PMID:23624135
reference_title: "Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease."
supports: PARTIAL
snippet: Patients with Addison's disease require lifelong treatment with glucocorticoids. At present, no glucocorticoid replacement therapy (GRT) can exactly mimic normal physiology.
explanation: The reference supports the need for glucocorticoid replacement therapy but does not specify prednisone.
- reference: PMID:35100642
reference_title: "[Adrenal gland diseases: Addison's Disease]."
supports: PARTIAL
snippet: Addison's disease typically results from the autoimmune destruction of the adrenal cortex and requires lifelong replacement with glucocorticoids and mineralocorticoids.
explanation: The reference supports the need for glucocorticoid replacement but does not specify prednisone.
- reference: PMID:33993277
reference_title: "Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study."
supports: PARTIAL
snippet: In primary but not in secondary adrenal insufficiency, mortality was higher with prednisolone.
explanation: The reference discusses prednisolone (a form of prednisone) but indicates higher mortality associated with its use in primary adrenal insufficiency.
treatment_term:
preferred_term: hormone modifying therapy
term:
id: MAXO:0000283
label: hormone modifying therapy
- name: Mineralocorticoid Replacement
description: Fludrocortisone to replace aldosterone and manage electrolyte balance.
evidence:
- reference: PMID:476980
reference_title: "Mineralocorticoid replacement in Addison's disease."
supports: SUPPORT
snippet: In four others, PRA remained normal throughout the study, even after fludrocortisone had been discontinued, suggesting that the drug was unnecessary for the maintenance of normal sodium balance in these patients.
explanation: The study indicates that fludrocortisone is used in the management of Addison's disease, although not all patients may require it for maintaining normal sodium balance.
- reference: PMID:24755997
reference_title: "Current and emerging therapies for Addison's disease."
supports: SUPPORT
snippet: Conventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone.
explanation: This confirms the use of fludrocortisone as part of the conventional therapy for Addison's disease.
- reference: PMID:25247653
reference_title: "Hydrocortisone replacement in disorders of sex development."
supports: SUPPORT
snippet: Many of these patients suffer from adrenal insufficiency and have to take either glucocorticoids or a combination of glucocorticoid and mineralocorticoid replacement therapy from birth to avoid life-threatening complications.
explanation: This reference supports the use of mineralocorticoid replacement therapy, which includes fludrocortisone, for managing adrenal insufficiency.
treatment_term:
preferred_term: hormone modifying therapy
term:
id: MAXO:0000283
label: hormone modifying therapy
- name: Salt Supplementation
description: Increased salt intake to manage hyponatremia.
evidence:
- reference: PMID:28132947
reference_title: "An Addison disease revealed with a serious hyponatremia."
supports: SUPPORT
snippet: Treatment involves normalisation of sodium concentration and corticosteroids replacement.
explanation: The literature mentions the normalization of sodium concentration as part of the treatment for Addison's disease, which supports the statement about increased salt intake.
- reference: PMID:20964584
reference_title: "Endocrine disorders: causes of hyponatremia not to neglect."
supports: PARTIAL
snippet: Primary adrenal insufficiency (i.e. Addison's disease) may well be recognized by clear hall-marks of the disease, such as pigmentation, salt craving, hypotension, and concomitant hyperkalemia.
explanation: The literature indicates salt craving as a hallmark of Addison's disease, supporting the need for increased salt intake.
- reference: PMID:18471672
reference_title: "Cerebral salt wasting syndrome: review."
supports: PARTIAL
snippet: Mineral corticoids may be useful in complicated cases.
explanation: While this reference mentions mineral corticoids, which are related to sodium balance, it does not explicitly support or refute increased salt intake.
treatment_term:
preferred_term: nutritional supplementation
term:
id: MAXO:0000106
label: nutritional supplementation
- name: Emergency Medical ID
description: Patients should carry an ID indicating their condition for emergency situations.
evidence:
- reference: PMID:19776201
reference_title: "Adrenal crisis in treated Addison's disease: a predictable but under-managed event."
supports: PARTIAL
snippet: The endocrinologist has a responsibility to ensure that Addison's patients have adequate access to life-saving emergency injection materials and repeated, practical training sessions in how to use them, while the general practitioner plays a vital role as in arranging prompt emergency admissions.
explanation: The literature emphasizes the importance of emergency preparedness for Addison's patients, which implicitly supports the need for carrying an ID indicating their condition.
- reference: PMID:31321757
reference_title: "Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults."
supports: PARTIAL
snippet: Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD.
explanation: The mention of continuous education and the ever-present danger of adrenal crisis supports the need for patients to carry an ID for emergency situations.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
- name: Stress Dose Adjustments
description: Increased dose of corticosteroids during illness or stress.
evidence:
- reference: PMID:18393745
reference_title: "Management of adrenal insufficiency during the stress of medical illness and surgery."
supports: SUPPORT
snippet: Patients with adrenal insufficiency (AI) require additional glucocorticoid doses during surgery or medical illness, but there is no universally accepted regimen for glucocorticoid supplementation therapy.
explanation: The literature supports the need for increased doses of corticosteroids during illness or stress for patients with Addison's Disease.
- reference: PMID:29544234
reference_title: "[Addisonian Crisis - Risk Assessment and Appropriate Treatment]."
supports: SUPPORT
snippet: An adrenal crisis (Addisonian crisis) is an acute life-threatening complication of adrenal insufficiency. It occurs when hydrocortisone demand is not met by supplementation in the context of an infection - often gastrointestinal, fever, trauma, acute psychological or physical stress.
explanation: The literature supports the need for increased doses of corticosteroids during stress to prevent adrenal crisis.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
notes: Prompt diagnosis and lifelong management with hormone replacement therapy are essential for preventing adrenal crises and maintaining health.
disease_term:
preferred_term: Addison disease
term:
id: MONDO:0015128
label: primary adrenal insufficiency
classifications:
harrisons_chapter:
- classification_value: endocrine system disorder
- classification_value: adrenal disorder
- classification_value: autoimmune disease
Disease Pathophysiology Research Report
Target Disease - Disease Name: Addison’s Disease (Primary Adrenal Insufficiency, PAI) - MONDO ID: not confirmed within retrieved sources; report focuses on mechanistic pathophysiology. - Category: Endocrine
Pathophysiology description (narrative) Primary adrenal insufficiency most commonly results from autoimmune adrenalitis in adults in developed regions. The autoimmune process targets the adrenal cortex, leading to progressive destruction of steroid‑producing cells in zona glomerulosa and zona fasciculata, with resultant mineralocorticoid and glucocorticoid deficiency. The dominant autoantigen is 21‑hydroxylase (CYP21A2), recognized by circulating autoantibodies and autoreactive T cells. Histopathology shows mononuclear (lymphocyte/plasma cell/macrophage) infiltration, loss of normal zonation, and end‑stage cortical atrophy/fibrosis; clinical insufficiency appears after extensive loss of functional cortex. A Th1‑biased immune response with IFN‑γ supports cytotoxic T‑cell activation and B‑cell autoantibody production, and antibody‑dependent and complement‑mediated mechanisms may contribute to injury. Polygenic susceptibility is strong, driven by HLA class II haplotypes (DR3‑DQ2 and DR4‑DQ8) and non‑HLA immune‑regulatory genes (e.g., CTLA4, PTPN22, BACH2, CLEC16A, NLRP1, CIITA, STAT4). Monogenic APS‑1 (AIRE mutations) causes a breakdown of central tolerance, predisposing to Addison’s disease; patients with APS‑1 frequently develop AAD alongside other autoimmune features. Iatrogenic checkpoint blockade (CTLA‑4/PD‑1 inhibitors) can precipitate primary adrenal insufficiency by releasing peripheral checkpoint control and promoting anti‑adrenal autoimmunity, sometimes accompanied by adrenal autoantibodies. Many patients with autoimmune Addison’s retain some residual adrenocortical function for years, and natural history studies and staging frameworks describe progression from potential/subclinical phases (antibody‑positive) through impaired reserve to overt failure characterized by low cortisol and aldosterone, with high ACTH and renin. Clinical manifestations map to hormone loss: glucocorticoid deficiency causes fatigue, weight loss, hypotension, and hypoglycemia; mineralocorticoid deficiency causes hyponatremia, hyperkalemia, salt craving, and abdominal pain; hyperpigmentation reflects chronic ACTH/α‑MSH elevation in primary disease. (gan2015pathophysiologyandnovel pages 30-35, gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2, betterle2019epidemiologypathogenesisand pages 2-3, betterle2019epidemiologypathogenesisand pages 8-10, wolff2023autoimmuneprimaryadrenal pages 11-11, wolff2023autoimmuneprimaryadrenal pages 1-2, betterle2019epidemiologypathogenesisand pages 1-2)
Key concepts and definitions (current understanding) - Autoimmune Addison’s disease (AAD): Primary adrenal failure due to immune‑mediated destruction of the adrenal cortex, often associated with 21‑hydroxylase autoantibodies and T‑cell responses; commonly part of autoimmune polyglandular syndromes. URL: https://doi.org/10.1007/s40618-019-01079-6 (2019‑07‑01) (betterle2019epidemiologypathogenesisand pages 1-2) - 21‑hydroxylase autoantibodies (21‑OHAbs): Highly disease‑specific serological markers; present in the majority of AAD and useful for diagnosis and risk prediction in preclinical stages. Landmark data show very high specificity and near‑universal positivity at clinical onset in autoimmune cohorts. URL: https://doi.org/10.1111/j.1365-2249.1997.262-ce1153.x (1997‑02); https://doi.org/10.1210/edrv.23.3.0466 (2002‑06) (betterle2002autoimmuneadrenalinsufficiency pages 1-2) - APS‑1 (AIRE deficiency): Monogenic syndrome of immune dysregulation with breakdown of central tolerance in the thymus; Addison’s disease is common within APS‑1. URL: https://doi.org/10.3389/fendo.2023.1285901 (2023‑11); https://doi.org/10.1038/s41574-022-00653-y (2022‑04) (røyrvik2022thegeneticsof pages 1-2, wolff2023autoimmuneprimaryadrenal pages 11-11) - HLA and non‑HLA genetic risk: HLA‑DR3‑DQ2 and DR4‑DQ8 haplotypes, plus non‑HLA loci (CTLA4, PTPN22, BACH2, CLEC16A, NLRP1, CIITA, STAT4), collectively explain a large fraction of heritable risk per the first AAD GWAS. URL: https://doi.org/10.1038/s41574-022-00653-y (2022‑04) (røyrvik2022thegeneticsof pages 1-2, røyrvik2022thegeneticsof pages 11-12) - Checkpoint inhibitor–induced PAI: Immune‑related adverse event of anti‑CTLA‑4/anti‑PD‑1 therapy; may feature adrenal autoantibodies and both primary and secondary AI. URL: https://doi.org/10.1016/j.iotech.2023.100374 (2023‑03) (wolff2023autoimmuneprimaryadrenal pages 11-11)
Recent developments and latest research (prioritize 2023–2024) - 2023 review of autoimmune PAI diagnostics: Confirms 21‑OHAb as first‑line serologic test, ACTH (250 µg) stimulation as the gold standard, and outlines genetic etiologies including immune defects and steroidogenesis genes; highlights emerging iatrogenic causes (checkpoint inhibitors) and polygenic risk insights. URL: https://doi.org/10.3389/fendo.2023.1285901 (2023‑11) (wolff2023autoimmuneprimaryadrenal pages 4-6, wolff2023autoimmuneprimaryadrenal pages 1-2) - Genetics (post‑GWAS synthesis): Nature Reviews Endocrinology (2022) summarizes GWAS findings attributing an unusually large proportion of AAD heritability (≈35–41%) to identified loci, with a dominant HLA signal and contributions from immune‑regulatory genes; also notes residual adrenocortical function in a subset and small trials of immunomodulation. URL: https://doi.org/10.1038/s41574-022-00653-y (2022‑04) (røyrvik2022thegeneticsof pages 1-2, røyrvik2022thegeneticsof pages 11-12) - APS and central tolerance (2024 NEJM review context captured in our evidence set as APS updates): Emphasizes the role of AIRE in APS‑1 and overlap with other APS phenotypes; supports central‑tolerance basis for AAD in APS‑1. URL: https://doi.org/10.1056/nejmra1713301 (2024‑03) (gan2015pathophysiologyandnovel pages 30-35) - Immune checkpoint inhibitor–associated AI (2023): Summarizes autoantibody profiles observed in primary and secondary AI following ICIs and mechanistic links to checkpoint pathways (CTLA‑4/PD‑1). URL: https://doi.org/10.1016/j.iotech.2023.100374 (2023‑03) (wolff2023autoimmuneprimaryadrenal pages 11-11)
Current applications and real‑world implementations - Diagnostics: 21‑OH autoantibodies are used to confirm autoimmune etiology; ACTH stimulation testing (250 µg) remains the gold standard to document cortisol deficiency; mineralocorticoid deficiency assessed by low aldosterone with high renin. URL: https://doi.org/10.3389/fendo.2023.1285901 (2023‑11) (wolff2023autoimmuneprimaryadrenal pages 4-6) - Risk staging and prediction: Natural history frameworks stage antibody‑positive individuals from potential AAD through subclinical to overt insufficiency, with renin rising early and ACTH‑stimulated cortisol response declining before basal cortisol falls. URL: https://doi.org/10.1007/s40618-019-01079-6 (2019‑07) (betterle2019epidemiologypathogenesisand pages 8-10) - Genetic evaluation: Monogenic causes (pediatric/early‑onset) and polygenic risk (HLA and non‑HLA) guide counseling and surveillance for associated autoimmunity. URL: https://doi.org/10.3389/fendo.2023.1285901 (2023‑11); https://doi.org/10.1038/s41574-022-00653-y (2022‑04) (wolff2023autoimmuneprimaryadrenal pages 1-2, røyrvik2022thegeneticsof pages 1-2) - ICI monitoring: Endocrine surveillance and autoantibody testing are applied in oncology clinics to detect and manage ICI‑related AI. URL: https://doi.org/10.1016/j.iotech.2023.100374 (2023‑03) (wolff2023autoimmuneprimaryadrenal pages 11-11)
Expert opinions and analysis from authoritative sources - “AAD is primarily caused by aberrant T cell behaviour” and shows an oligogenic architecture with strong HLA influence and shared autoimmune loci; central and peripheral tolerance defects are central to pathogenesis. URL: https://doi.org/10.1038/s41574-022-00653-y (2022‑04) (røyrvik2022thegeneticsof pages 1-2) - Autoantibodies against P450c21 are established diagnostic biomarkers, while cytotoxic CD8+ T cells restricted by HLA class I recognize 21‑OH epitopes, supporting a CD8‑driven effector mechanism in tissue destruction. URL: https://doi.org/10.3389/fendo.2023.1285901 (2023‑11) (wolff2023autoimmuneprimaryadrenal pages 11-11) - Clinically, autoimmune etiologies account for the majority of adult AD in developed countries, with frequent coexisting autoimmunity, and rising prevalence compared with historical infectious causes. URL: https://doi.org/10.1007/s40618-019-01079-6 (2019‑07) (betterle2019epidemiologypathogenesisand pages 1-2)
Relevant statistics and data from recent studies - Serology: In a large autoimmune cohort, adrenal cortex and/or 21‑OHAbs were detectable in essentially all patients at clinical onset, supporting high sensitivity at presentation and high specificity for AAD in endocrine autoimmune populations. URL: https://doi.org/10.1111/j.1365-2249.1997.262-ce1153.x (1997‑02); https://doi.org/10.1210/edrv.23.3.0466 (2002‑06) (betterle2002autoimmuneadrenalinsufficiency pages 1-2) - Genetics (GWAS): The 2021 AAD GWAS summarized in 2022 assigns ≈35–41% of heritability to identified loci, with the leading HLA signal (OR ~6) and additional non‑HLA signals (e.g., CLEC16A, SULT1A2‑labelled region). URL: https://doi.org/10.1038/s41574-022-00653-y (2022‑04) (røyrvik2022thegeneticsof pages 1-2, røyrvik2022thegeneticsof pages 11-12) - Epidemiology: European incidence roughly 4.4–6.2/million/year; prevalence varies from single digits/million in some Asian regions to >200/million in Iceland; autoimmunity accounts for ~75–96% of adult cases in Europe. URL: https://doi.org/10.1007/s40618-019-01079-6 (2019‑07) (betterle2019epidemiologypathogenesisand pages 1-2) - Natural history staging: Progressive rise in renin and fall in aldosterone precede overt glucocorticoid failure; ACTH rises with declining cortisol reserve; staging frameworks delineate potential/subclinical/overt phases. URL: https://doi.org/10.1007/s40618-019-01079-6 (2019‑07) (betterle2019epidemiologypathogenesisand pages 8-10)
1) Core Pathophysiology - Primary mechanisms: Organ‑specific autoimmunity against steroidogenic enzymes (dominantly CYP21A2) with Th1‑biased CD4+ responses and HLA‑restricted cytotoxic CD8+ T‑cell effectors; humoral autoimmunity (21‑OHAbs) serves as biomarker and may contribute via ADCC/complement. Histology shows lymphocytic adrenalitis progressing to cortical atrophy/fibrosis. (gan2015pathophysiologyandnovel pages 30-35, gan2015pathophysiologyandnovel pages 39-46, wolff2023autoimmuneprimaryadrenal pages 11-11) - Dysregulated molecular pathways: T‑cell activation/negative regulation (CTLA4, PTPN22), antigen presentation (HLA‑DR/DQ, CIITA), innate inflammatory signaling (NLRP1), and immune cell differentiation (BACH2, STAT4); steroidogenesis disrupted downstream of enzyme loss/damage. (gan2015pathophysiologyandnovel pages 39-46, betterle2019epidemiologypathogenesisand pages 2-3, røyrvik2022thegeneticsof pages 1-2) - AIRE/APS‑1: Defective central tolerance in thymic mTECs (AIRE) leads to survival of autoreactive clones; APS‑1 commonly includes Addison’s disease. (røyrvik2022thegeneticsof pages 1-2, gan2015pathophysiologyandnovel pages 30-35) - ICI‑PAI: CTLA‑4/PD‑1 blockade removes key brakes on T‑cell responses, enabling anti‑adrenal autoimmunity; autoantibodies may be present in some cases. (wolff2023autoimmuneprimaryadrenal pages 11-11)
2) Key Molecular Players (selected) - Genes/Proteins: CYP21A2 (21‑hydroxylase), AIRE, HLA‑DR/DQ haplotypes (DR3‑DQ2; DR4‑DQ8), CTLA4, PTPN22, BACH2, CLEC16A, NLRP1, CIITA, STAT4. (betterle2002autoimmuneadrenalinsufficiency pages 1-2, røyrvik2022thegeneticsof pages 1-2, gan2015pathophysiologyandnovel pages 39-46, betterle2019epidemiologypathogenesisand pages 2-3) - Chemical entities: Cortisol (CHEBI:27732), Aldosterone (CHEBI:16630), 17‑hydroxyprogesterone (CHEBI:17656); immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab). (betterle2019epidemiologypathogenesisand pages 1-2, betterle2019epidemiologypathogenesisand pages 8-10, wolff2023autoimmuneprimaryadrenal pages 1-2, wolff2023autoimmuneprimaryadrenal pages 11-11) - Cell Types: CD8+ cytotoxic T cells, Th1 CD4+ T cells, B cells; adrenal cortical cells (ZG/ZF). (wolff2023autoimmuneprimaryadrenal pages 11-11, gan2015pathophysiologyandnovel pages 39-46, gan2015pathophysiologyandnovel pages 30-35) - Anatomical Locations: Adrenal cortex (UBERON:0002108), zona glomerulosa/fasciculata. (gan2015pathophysiologyandnovel pages 30-35, betterle2019epidemiologypathogenesisand pages 8-10)
| Category | Standard ID | Name | Role in pathophysiology (1–2 sentences) | Key pathway / GO terms | Evidence | Notes (assay type, localization) |
|---|---|---|---|---|---|---|
| Gene/Protein | HGNC:CYP21A2 | CYP21A2 (21‑hydroxylase) | Major adrenal autoantigen; target of autoantibodies and autoreactive T cells whose loss impairs conversion steps in cortisol/aldosterone synthesis leading to PAI. | GO:0006694 (steroid biosynthetic process), GO:0005783 (endoplasmic reticulum) | (betterle2002autoimmuneadrenalinsufficiency pages 1-2, gan2015pathophysiologyandnovel pages 30-35) | Autoantibody assays (21‑OH Ab ELISA/RI); enzyme localized to ER/microsomes |
| Gene/Protein | HGNC:AIRE | AIRE | Transcriptional regulator in thymic medullary epithelial cells that promotes central tolerance; biallelic loss → APS‑1 with early autoimmune adrenal destruction. | GO:0002250 (adaptive immune response), GO:0002376 (immune system process) | (røyrvik2022thegeneticsof pages 1-2, wolff2023autoimmuneprimaryadrenal pages 11-11) | Genetic testing (NGS); protein expressed in thymic mTECs (central tolerance) |
| Gene/Protein | HLA‑DRB1/DQA1/DQB1 | HLA‑DR/DQ (DR3‑DQ2, DR4‑DQ8) | Class II haplotypes strongly increase risk via altered peptide presentation to CD4+ T cells and shaping autoreactive responses. | GO:0019882 (antigen processing and presentation) | (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) | HLA typing; surface MHC II on antigen‑presenting cells |
| Gene/Protein | HGNC:CTLA4 | CTLA4 | Immune‑checkpoint regulator; risk variants / altered soluble CTLA4 reduce peripheral T‑cell inhibition and predispose to loss of tolerance. | GO:0050856 (negative regulation of T cell receptor signaling pathway) | (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) | Genotyping; protein on Tregs/activated T cells, target of ipilimumab |
| Gene/Protein | HGNC:PTPN22 | PTPN22 | Tyrosine phosphatase modulating TCR signaling; risk alleles perturb T‑cell selection/activation and associate with AAD. | GO:0007165 (signal transduction) | (røyrvik2022thegeneticsof pages 1-2) | Genotyping; intracellular lymphocyte phosphatase |
| Gene/Protein | HGNC:BACH2 | BACH2 | Transcription factor controlling B‑ and T‑cell differentiation and tolerance; variants associated with autoimmunity and AAD susceptibility. | GO:0006355 (regulation of transcription), GO:0002250 (adaptive immune response) | (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) | Genotyping; lymphocyte nuclear TF |
| Gene/Protein | HGNC:CLEC16A | CLEC16A | GWAS‑implicated locus linked to antigen presentation/autophagy pathways and general autoimmune risk; contributes to polygenic susceptibility. | GO:0006897 (endocytosis), GO:0002376 (immune system process) | (røyrvik2022thegeneticsof pages 1-2) | Genotyping; endosomal/autophagy‑related function |
| Gene/Protein | HGNC:NLRP1 | NLRP1 | Inflammasome component; variants implicated in autoimmunity/inflammatory responses that may modulate adrenal inflammation. | GO:0006954 (inflammatory response) | (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) | Genotyping; expressed in myeloid cells, inflammasome assays |
| Gene/Protein | HGNC:CIITA | CIITA | Master regulator of MHC class II expression; variation can alter antigen presentation and influence autoimmunity risk. | GO:0019882 (antigen processing and presentation) | (betterle2019epidemiologypathogenesisand pages 2-3) | Genotyping; transcriptional regulator of HLA expression |
| Gene/Protein | HGNC:STAT4 | STAT4 | Transcription factor promoting Th1 differentiation (IFN‑γ pathway); implicated in directing Th1‑biased responses in AAD. | GO:0042093 (T helper 1 type immune response) | (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) | Phospho‑STAT assays; activated downstream of cytokine receptors |
| Cell type | CL:0000629 | CD8+ cytotoxic T cell | Effector cells that recognize adrenal peptides (including 21‑OH epitopes) on HLA and mediate cytotoxic destruction of adrenal cortical cells. | GO:0002250 (adaptive immune response), GO:0042093 (Th1 response context) | (wolff2023autoimmuneprimaryadrenal pages 11-11, gan2015pathophysiologyandnovel pages 39-46) | Detected by tetramers/ELISPOT; HLA‑A2/epitope‑restricted cytotoxicity assays |
| Cell type | CL:0000548 | Th1 CD4+ T helper cell | Produces IFN‑γ and supports macrophage and CD8+ responses; Th1 bias implicated in AAD immunopathology. | GO:0042093 (T helper 1 type immune response), GO:0002250 (adaptive immune response) | (gan2015pathophysiologyandnovel pages 39-46, wolff2023autoimmuneprimaryadrenal pages 11-11) | Cytokine profiling (IFN‑γ), intracellular staining |
| Cell type | CL:0000236 | B cell | Source of autoreactive 21‑OH autoantibodies used as diagnostic/prognostic markers and contributors to humoral immunity in AAD. | GO:0002250 (adaptive immune response), GO:0006955 (immune response) | (betterle2002autoimmuneadrenalinsufficiency pages 1-2, gan2015pathophysiologyandnovel pages 39-46) | Autoantibody ELISA/RIA; memory B‑cell assays |
| Anatomical site | UBERON:0002108 | Adrenal cortex (zona glomerulosa / zona fasciculata) | Tissue compartments that synthesize aldosterone (ZG) and cortisol (ZF); primary target of lymphocytic adrenalitis leading to mineralocorticoid/glucocorticoid deficiency. | GO:0006694 (steroid biosynthetic process) | (gan2015pathophysiologyandnovel pages 30-35, betterle2019epidemiologypathogenesisand pages 8-10) | Histopathology (lymphocytic infiltration, atrophy/fibrosis); imaging/pathology |
| Chemical/Drug | CHEBI:27732 | Cortisol | Principal glucocorticoid deficient in AAD; low serum/urinary cortisol with compensatory high ACTH underlies many clinical features (hypotension, hypoglycemia, fatigue). | GO:0006694 (steroid biosynthetic process) | (betterle2019epidemiologypathogenesisand pages 1-2, betterle2019epidemiologypathogenesisand pages 8-10) | Measured by immunoassay or LC‑MS/MS; endocrine functional tests (ACTH stimulation) |
| Chemical/Drug | CHEBI:16630 | Aldosterone | Mineralocorticoid whose loss (with high renin) causes hyponatremia, hyperkalemia and salt‑craving in PAI. | GO:0006694 (steroid biosynthetic process) | (betterle2019epidemiologypathogenesisand pages 1-2, betterle2019epidemiologypathogenesisand pages 8-10) | Measured by immunoassay/LC‑MS/MS; renin/aldosterone ratio assays |
| Chemical/Drug | CHEBI:17656 | 17‑Hydroxyprogesterone | Steroid precursor upstream of cortisol; biochemical alterations appear in steroidogenic defects and are informative in differential/genetic workup. | GO:0006694 (steroid biosynthetic process) | (gan2015pathophysiologyandnovel pages 30-35) | Measured by LC‑MS/MS; elevated in congenital steroidogenic enzyme defects |
| Chemical/Drug | N/A | Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) | Therapies that block CTLA‑4/PD‑1 checkpoints and can precipitate iatrogenic autoimmune adrenalitis/PAI by unleashing autoreactive T cells; may be associated with adrenal autoantibodies in some cases. | GO:0002250 (adaptive immune response), GO:0050856 (checkpoint regulation context) | (wolff2023autoimmuneprimaryadrenal pages 1-2, wolff2023autoimmuneprimaryadrenal pages 11-11) | Clinical history/medication record; endocrine monitoring and autoantibody testing during ICI therapy |
Table: Table summarizing genes/proteins, immune cells, hormones, anatomical sites and drugs relevant to autoimmune primary adrenal insufficiency, with roles, GO pathway tags, evidence pointers (pqac‑IDs) and common assays/localizations; useful as a quick annotated reference for mechanistic and diagnostic links.
3) Biological Processes (for GO annotation) - Antigen processing and presentation (GO:0019882); adaptive immune response (GO:0002250); T helper 1 type immune response (GO:0042093); negative regulation of TCR signaling (GO:0050856); inflammatory response (GO:0006954); steroid biosynthetic process (GO:0006694). (røyrvik2022thegeneticsof pages 1-2, gan2015pathophysiologyandnovel pages 39-46, gan2015pathophysiologyandnovel pages 30-35)
4) Cellular Components - Endoplasmic reticulum (21‑hydroxylase localization) and mitochondria (steroidogenesis initiation); cell surface MHC molecules on APCs; adrenal cortical extracellular milieu where infiltrates accumulate; fibrotic stroma in end‑stage glands. (gan2015pathophysiologyandnovel pages 30-35, gan2015pathophysiologyandnovel pages 39-46)
5) Disease Progression - Preclinical/“potential” AAD: 21‑OHAb positivity, normal basal hormones; earliest changes include rising renin and declining aldosterone while ACTH‑stimulated cortisol remains normal. (betterle2019epidemiologypathogenesisand pages 8-10) - Subclinical stages: Progressive blunting then loss of cortisol response to ACTH; ACTH rises; aldosterone decreases further with high renin. (betterle2019epidemiologypathogenesisand pages 8-10) - Overt AAD: Low cortisol, high ACTH; low aldosterone with high renin; histology shows marked lymphocytic infiltration and cortical atrophy/fibrosis; many retain minimal residual secretion. (gan2015pathophysiologyandnovel pages 30-35, betterle2019epidemiologypathogenesisand pages 8-10, røyrvik2022thegeneticsof pages 11-12)
6) Phenotypic Manifestations (with mechanistic links) - Hyperpigmentation (HP:0000953): Chronic ACTH/α‑MSH elevation in primary disease; melanocortin receptor stimulation drives pigmentation. (betterle2019epidemiologypathogenesisand pages 1-2) - Hypotension (HP:0002615), fatigue (HP:0012378), weight loss (HP:0001824), hypoglycemia (HP:0001943): Glucocorticoid deficiency reduces vascular tone/gluconeogenesis and increases cytokine tone. (betterle2019epidemiologypathogenesisand pages 1-2) - Hyponatremia (HP:0002902), hyperkalemia (HP:0002153), salt craving (HP:0002660), abdominal pain (HP:0003270): Mineralocorticoid deficiency (low aldosterone) with compensatory high renin. (wolff2023autoimmuneprimaryadrenal pages 4-6, betterle2019epidemiologypathogenesisand pages 1-2) - Adrenal crisis (HP:0100704): Acute decompensation with hypotension/shock, often precipitated by stressors in unrecognized or undertreated disease. (betterle2019epidemiologypathogenesisand pages 1-2)
Gene/protein annotations with ontology terms - HGNC: CYP21A2 (21‑hydroxylase); GO:0006694 (steroid biosynthesis), GO:0005783 (ER). (gan2015pathophysiologyandnovel pages 30-35, betterle2002autoimmuneadrenalinsufficiency pages 1-2) - HGNC: AIRE; GO:0002250 (adaptive immune response), GO:0002376 (immune system process). (røyrvik2022thegeneticsof pages 1-2) - HLA‑DRB1/DQA1/DQB1 haplotypes; GO:0019882 (antigen presentation). (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) - HGNC: CTLA4; GO:0050856 (negative regulation of TCR signaling). (gan2015pathophysiologyandnovel pages 39-46, røyrvik2022thegeneticsof pages 1-2) - HGNC: PTPN22; GO:0007165 (signal transduction). (røyrvik2022thegeneticsof pages 1-2) - HGNC: BACH2, CLEC16A, NLRP1, CIITA, STAT4; GO terms as in artifact. (røyrvik2022thegeneticsof pages 1-2, betterle2019epidemiologypathogenesisand pages 2-3, gan2015pathophysiologyandnovel pages 39-46)
Phenotype associations (HP terms) - HP:0000953 Hyperpigmentation; HP:0002615 Hypotension; HP:0002902 Hyponatremia; HP:0002153 Hyperkalemia; HP:0012378 Fatigue; HP:0001824 Weight loss; HP:0001943 Hypoglycemia; HP:0100704 Adrenal crisis. (betterle2019epidemiologypathogenesisand pages 1-2, wolff2023autoimmuneprimaryadrenal pages 4-6)
Cell type involvement (CL terms) - CL:0000629 CD8+ T cell; CL:0000548 Th1 CD4+ T cell; CL:0000236 B cell; adrenal cortical steroidogenic cells as tissue targets. (wolff2023autoimmuneprimaryadrenal pages 11-11, gan2015pathophysiologyandnovel pages 39-46, gan2015pathophysiologyandnovel pages 30-35)
Anatomical locations (UBERON terms) - UBERON:0002108 Adrenal cortex; zonal substructures (ZG/ZF) as functional units for aldosterone and cortisol synthesis. (gan2015pathophysiologyandnovel pages 30-35)
Chemical entities (CHEBI terms) - CHEBI:27732 Cortisol; CHEBI:16630 Aldosterone; CHEBI:17656 17‑hydroxyprogesterone. (betterle2019epidemiologypathogenesisand pages 1-2, betterle2019epidemiologypathogenesisand pages 8-10, gan2015pathophysiologyandnovel pages 30-35)
Evidence items (with PMIDs/DOIs/URLs and dates where available) - Wolff ASB, Kucuka I, Oftedal BE. Autoimmune primary adrenal insufficiency—current diagnostic approaches and future perspectives. Front Endocrinol. 2023‑11. doi:10.3389/fendo.2023.1285901; URL: https://doi.org/10.3389/fendo.2023.1285901 (wolff2023autoimmuneprimaryadrenal pages 4-6, wolff2023autoimmuneprimaryadrenal pages 1-2, wolff2023autoimmuneprimaryadrenal pages 11-11) - Røyrvik EC, Husebye ES. The genetics of autoimmune Addison disease: past, present and future. Nat Rev Endocrinol. 2022‑04. doi:10.1038/s41574-022-00653-y; URL: https://doi.org/10.1038/s41574-022-00653-y (røyrvik2022thegeneticsof pages 1-2, røyrvik2022thegeneticsof pages 11-12) - Betterle C, Presotto F, Furmaniak J. Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults. J Endocrinol Invest. 2019‑07. doi:10.1007/s40618-019-01079-6; URL: https://doi.org/10.1007/s40618-019-01079-6 (betterle2019epidemiologypathogenesisand pages 1-2, betterle2019epidemiologypathogenesisand pages 8-10, betterle2019epidemiologypathogenesisand pages 2-3) - Winqvist O, Karlsson F, Kämpe O. 21‑hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet. 1992‑06. doi:10.1016/0140-6736(92)91829-W; URL: https://doi.org/10.1016/0140-6736(92)91829-w (betterle2002autoimmuneadrenalinsufficiency pages 1-2) - Falorni A, et al. 21‑hydroxylase autoantibodies are highly specific for Addison’s disease. Clin Exp Immunol. 1997‑02. doi:10.1111/j.1365-2249.1997.262-ce1153.x; URL: https://doi.org/10.1111/j.1365-2249.1997.262-ce1153.x (betterle2002autoimmuneadrenalinsufficiency pages 1-2) - Helderman NC, Lucas MW, Blank C. Autoantibodies in adrenal insufficiency after immune checkpoint inhibitors. Immuno‑Oncol Technol. 2023‑03. doi:10.1016/j.iotech.2023.100374; URL: https://doi.org/10.1016/j.iotech.2023.100374 (wolff2023autoimmuneprimaryadrenal pages 11-11) - Husebye ES, Anderson MS, Kämpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med. 2024‑03. doi:10.1056/NEJMra1713301; URL: https://doi.org/10.1056/nejmra1713301 (gan2015pathophysiologyandnovel pages 30-35) - Gan EH. Pathophysiology and novel therapeutic approaches in autoimmune Addison’s disease. Thesis (2015). Mechanistic synthesis of Th1/CD8+ and histopathology features. (gan2015pathophysiologyandnovel pages 30-35, gan2015pathophysiologyandnovel pages 39-46)
Direct quotes (supporting statements) - “AAD is primarily caused by aberrant T cell behaviour” and risk is “oligogenic” with a “dominant HLA signal” (Nature Reviews Endocrinology 2022). URL: https://doi.org/10.1038/s41574-022-00653-y (røyrvik2022thegeneticsof pages 1-2) - “Autoantibodies against adrenal cytochrome P450 enzymes, notably 21‑hydroxylase (P450c21), are established markers; … high frequencies of cytolytic 21‑hydroxylase–specific CD8+ T cells … support a CD8‑driven effector mechanism.” (Wolff et al. 2023). URL: https://doi.org/10.3389/fendo.2023.1285901 (wolff2023autoimmuneprimaryadrenal pages 11-11) - Natural history staging shows progression “from potential Addison’s disease through subclinical stages to overt insufficiency,” with early renin rise and aldosterone decline and later ACTH increase with cortisol failure (Betterle et al. 2019). URL: https://doi.org/10.1007/s40618-019-01079-6 (betterle2019epidemiologypathogenesisand pages 8-10)
Limitations and open questions - While 21‑OHAbs are highly specific and sensitive at onset, standardized performance metrics vary across assays and cohorts; residual function suggests heterogeneity in tissue destruction and potential windows for immunomodulation. Larger, diverse genetic studies are needed to refine non‑HLA loci and ancestry‑specific risks. (betterle2002autoimmuneadrenalinsufficiency pages 1-2, røyrvik2022thegeneticsof pages 11-12)
Conclusion Autoimmune Addison’s disease results from a confluence of genetic susceptibility (HLA and multiple immune‑regulatory loci), defects in immune tolerance (including AIRE in APS‑1), and effector immune mechanisms (Th1 polarization and HLA‑restricted cytotoxic CD8+ T cells) targeting adrenal steroidogenic cells, most prominently via 21‑hydroxylase. Clinical and laboratory phenotypes follow predictable hormonal deficits, and contemporary practice integrates serology (21‑OHAbs), dynamic testing (ACTH stimulation), and genetic/iatrogenic risk assessment (including checkpoint blockade) to diagnose and manage disease across its natural history. Ongoing research emphasizes early detection in antibody‑positive individuals, refinement of genetic risk, and exploration of targeted immunomodulation to preserve residual adrenal function. (røyrvik2022thegeneticsof pages 1-2, wolff2023autoimmuneprimaryadrenal pages 4-6, betterle2019epidemiologypathogenesisand pages 8-10, wolff2023autoimmuneprimaryadrenal pages 11-11, gan2015pathophysiologyandnovel pages 30-35)
References
(gan2015pathophysiologyandnovel pages 30-35): EH Gan. Pathophysiology and novel therapeutic approaches in autoimmune addison's disease. Unknown journal, 2015.
(gan2015pathophysiologyandnovel pages 39-46): EH Gan. Pathophysiology and novel therapeutic approaches in autoimmune addison's disease. Unknown journal, 2015.
(røyrvik2022thegeneticsof pages 1-2): Ellen C. Røyrvik and Eystein S. Husebye. The genetics of autoimmune addison disease: past, present and future. Nature Reviews Endocrinology, 18:399-412, Apr 2022. URL: https://doi.org/10.1038/s41574-022-00653-y, doi:10.1038/s41574-022-00653-y. This article has 28 citations and is from a domain leading peer-reviewed journal.
(betterle2019epidemiologypathogenesisand pages 2-3): Corrado Betterle, F. Presotto, and J. Furmaniak. Epidemiology, pathogenesis, and diagnosis of addison’s disease in adults. Journal of Endocrinological Investigation, 42:1407-1433, Jul 2019. URL: https://doi.org/10.1007/s40618-019-01079-6, doi:10.1007/s40618-019-01079-6. This article has 161 citations and is from a peer-reviewed journal.
(betterle2019epidemiologypathogenesisand pages 8-10): Corrado Betterle, F. Presotto, and J. Furmaniak. Epidemiology, pathogenesis, and diagnosis of addison’s disease in adults. Journal of Endocrinological Investigation, 42:1407-1433, Jul 2019. URL: https://doi.org/10.1007/s40618-019-01079-6, doi:10.1007/s40618-019-01079-6. This article has 161 citations and is from a peer-reviewed journal.
(wolff2023autoimmuneprimaryadrenal pages 11-11): Anette S. B. Wolff, Isil Kucuka, and Bergithe E. Oftedal. Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives. Frontiers in Endocrinology, Nov 2023. URL: https://doi.org/10.3389/fendo.2023.1285901, doi:10.3389/fendo.2023.1285901. This article has 16 citations and is from a poor quality or predatory journal.
(wolff2023autoimmuneprimaryadrenal pages 1-2): Anette S. B. Wolff, Isil Kucuka, and Bergithe E. Oftedal. Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives. Frontiers in Endocrinology, Nov 2023. URL: https://doi.org/10.3389/fendo.2023.1285901, doi:10.3389/fendo.2023.1285901. This article has 16 citations and is from a poor quality or predatory journal.
(betterle2019epidemiologypathogenesisand pages 1-2): Corrado Betterle, F. Presotto, and J. Furmaniak. Epidemiology, pathogenesis, and diagnosis of addison’s disease in adults. Journal of Endocrinological Investigation, 42:1407-1433, Jul 2019. URL: https://doi.org/10.1007/s40618-019-01079-6, doi:10.1007/s40618-019-01079-6. This article has 161 citations and is from a peer-reviewed journal.
(betterle2002autoimmuneadrenalinsufficiency pages 1-2): Corrado Betterle, Chiara Dal Pra, Franco Mantero, and Renato Zanchetta. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocrine Reviews, 23:327-364, Jun 2002. URL: https://doi.org/10.1210/edrv.23.3.0466, doi:10.1210/edrv.23.3.0466. This article has 1032 citations and is from a domain leading peer-reviewed journal.
(røyrvik2022thegeneticsof pages 11-12): Ellen C. Røyrvik and Eystein S. Husebye. The genetics of autoimmune addison disease: past, present and future. Nature Reviews Endocrinology, 18:399-412, Apr 2022. URL: https://doi.org/10.1038/s41574-022-00653-y, doi:10.1038/s41574-022-00653-y. This article has 28 citations and is from a domain leading peer-reviewed journal.
(wolff2023autoimmuneprimaryadrenal pages 4-6): Anette S. B. Wolff, Isil Kucuka, and Bergithe E. Oftedal. Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives. Frontiers in Endocrinology, Nov 2023. URL: https://doi.org/10.3389/fendo.2023.1285901, doi:10.3389/fendo.2023.1285901. This article has 16 citations and is from a poor quality or predatory journal.